Whitehawk Therapeutics, Inc. (WHWK): who owns it and who trades it
As of Nov 16, 2026, WHWK insiders reported 14 open-market sales worth $2.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was David James Lennon (CEO), with $1.1M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Whitehawk Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns WHWK
79 funds and institutions reported WHWK shares worth $198M at the end of Q2 2026, about 92% of the company. The largest holder is Yu Fan with 10.3%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Yu Fan | 4.86M | 10.30% | $22.3M | +135% |
| Acuta Capital Partners, LLC | 4.69M | 9.93% | $21.5M | +37% |
| QVT Financial LP | 4.62M | 9.78% | $21.1M | No change |
| Montanova Capital, LLC | 4.30M | 9.11% | $19.7M | +16% |
| Orbimed Advisors LLC | 3.93M | 8.34% | $18M | -6% |
| Avoro Capital Advisors LLC | 2.85M | 6.04% | $13.1M | No change |
| Siren, L.L.C. | 2.34M | 4.95% | $10.7M | +12% |
| KVP Capital Advisors, LP | 2.17M | 4.59% | $9.9M | No change |
| BlackRock, Inc. | 1.92M | 4.07% | $8.8M | +447% |
| Vanguard Capital Management LLC | 1.39M | 2.94% | $6.4M | +6% |
| ADAR1 Capital Management, LLC | 1.34M | 2.84% | $6.1M | +944% |
| Acorn Capital Advisors, LLC | 1.14M | 2.41% | $5.2M | No change |
| Stempoint Capital LP | 1.02M | 2.16% | $4.7M | -46% |
| Geode Capital Management, LLC | 899,780 | 1.91% | $4.1M | +97% |
| Ally Bridge Group (NY) LLC | 817,939 | 1.73% | $3.7M | No change |
| Woodline Partners LP | 436,614 | 0.93% | $2M | +55% |
| Renaissance Technologies LLC | 413,822 | 0.88% | $1.9M | -3% |
| State Street Corp | 386,982 | 0.82% | $1.8M | +141% |
| Millennium Management LLC | 380,406 | 0.81% | $1.7M | +23% |
| Eversept Partners, LP | 303,306 | 0.64% | $1.4M | -1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, WHWK insiders reported $0 of open-market purchases and $2.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | Scott M. Giacobello | CFO | Sale | 141,600 | $4.13 | $585K | Form 4 |
| Apr 15, 2026 | Scott M. Giacobello | CFO | Sale | 77,000 | $3.86 | $297K | Form 4 |
| Apr 14, 2026 | Bryan Ball | See remarks | Sale | 92,460 | $3.64 | $337K | Form 4 |
| Apr 13, 2026 | Bryan Ball | See remarks | Sale | 26,389 | $3.46 | $91.3K | Form 4 |
| Apr 10, 2026 | Bryan Ball | See remarks | Sale | 6,596 | $3.43 | $22.6K | Form 4 |
| Apr 9, 2026 | Bryan Ball | See remarks | Sale | 50,000 | $3.57 | $178K | Form 4 |
| Apr 9, 2026 | David James Lennon | CEO | Sale | 14,500 | $3.38 | $49K | Form 4 |
| Apr 8, 2026 | David James Lennon | CEO | Sale | 63,945 | $3.40 | $217K | Form 4 |
| Apr 7, 2026 | David James Lennon | CEO | Sale | 94,087 | $3.43 | $323K | Form 4 |
| Apr 6, 2026 | David James Lennon | CEO | Sale | 102,395 | $3.51 | $359K | Form 4 |
| Apr 2, 2026 | David James Lennon | CEO | Sale | 26,858 | $3.48 | $93.5K | Form 4 |
| Mar 2, 2026 | David James Lennon | CEO | Sale | 5,100 | $3.31 | $16.9K | Form 4 |
| Mar 2, 2026 | Scott M. Giacobello | CFO | Sale | 2,594 | $3.31 | $8.6K | Form 4 |
| Mar 2, 2026 | Bryan Ball | See remarks | Sale | 1,834 | $3.31 | $6.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David James Lennon | CHIEF EXECUTIVE OFFICER, Director | – | $1.1M | Apr 9, 2026 |
| Scott M. Giacobello | CHIEF FINANCIAL OFFICER | – | $891K | Apr 16, 2026 |
| Bryan Ball | See remarks | – | $635K | Apr 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
WHWK short interest
Low short interest. 4.4% of WHWK shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went up 191%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.49M WHWK shares were sold short, 4.4% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 318,468 shares, buying them all back would take about 7.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.49M | 4.36% | -5% | 318,468 | 7.8 |
| Oct 15, 2026 | 2.62M | 4.60% | -3% | 354,151 | 7.4 |
| Sep 30, 2026 | 2.71M | 4.75% | -1% | 382,262 | 7.1 |
| Sep 15, 2026 | 2.73M | 4.78% | -9% | 292,559 | 9.3 |
| Aug 31, 2026 | 2.98M | 5.23% | -41% | 238,372 | 12.5 |
| Aug 14, 2026 | 5.03M | 8.83% | +14% | 482,729 | 10.4 |
| Jul 31, 2026 | 4.43M | 9.39% | +6% | 428,016 | 10.3 |
| Jul 15, 2026 | 4.18M | 8.86% | +47% | 552,443 | 7.6 |
| Jun 30, 2026 | 2.83M | 6.00% | +140% | 824,119 | 3.4 |
| Jun 15, 2026 | 1.18M | 2.50% | +40% | 213,093 | 5.5 |
| May 29, 2026 | 843,660 | 1.79% | -1% | 338,023 | 2.5 |
| May 15, 2026 | 854,980 | 1.81% | +4% | 616,889 | 1.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Whitehawk Therapeutics company events
Whitehawk Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Sep 10, 2026LeadershipThe board of directors of Whitehawk Therapeutics, Inc. increased the number of its authorized directors from nine to ten, and appointed Vijay Iyengar, M.D. to fill the newly created opening on the Board, effective September 9, 2026. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 21, 2026AnnouncementWhitehawk Therapeutics, Inc. issued a press release announcing, among other things, (i) the expansion of the Company’s antibody drug conjugate pipeline through an option agreement with Hangzhou DAC Biotechnology which provides access to the linker-payload CPT113 for use in up to five additional ADC… Filing
- May 13, 2026AgreementWhitehawk Therapeutics, Inc. entered into a Securities Purchase Agreement with each of the purchasers named therein, pursuant to which the Company agreed to sell to the PIPE Investors (i) 4,330,866 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $3.92 per… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Whitehawk Therapeutics financials
Famous investors that hold WHWK
4 of the 50 well-known investors we track reported holding WHWK in their latest 13F filing. The largest position is Jim Simons's, worth $2.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 663,922 | $2.5M | 0.0% | +60% |
| Israel Englander · Millennium Management | Q3 2026 | 442,900 | $1.7M | 0.0% | +16% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 18,012 | $67.7K | 0.0% | -68% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 15,056 | $56.6K | 0.0% | -50% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named WHWK in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Dellora Investments LP | 13G | 5.6% |
| Nov 16, 2026 | Dellora Investments LP | 13G | 5.6% |
| Nov 16, 2026 | ABG Management Ltd. | 13G/A | 0.0% |
| Nov 16, 2026 | ABG Management Ltd. | 13G/A | 0.0% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 6.2% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 6.2% |
Questions about Whitehawk Therapeutics, Inc. (WHWK) stock
Who owns the most WHWK stock?
The largest reported owner of Whitehawk Therapeutics, Inc. (WHWK) is Yu Fan, with 10.3% of the company. In total, 79 funds and institutions reported holding WHWK at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are WHWK insiders buying or selling?
In the last 12 months, WHWK insiders reported no open-market purchases and 14 sales worth $2.6M. The latest trade was on Apr 16, 2026. See every trade.
What is the short interest in WHWK?
As of Oct 30, 2026, 2.49M WHWK shares were sold short, 4.4% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 318,468 shares, buying them all back would take about 7.8 trading days (days to cover). See the history.
Which famous investors hold WHWK?
4 of the 50 well-known investors we track reported WHWK in their latest 13F filing, including Jim Simons, Israel Englander, Steve Cohen. The largest position is worth $2.5M. See all holders.
Executive pay
Whitehawk Therapeutics's chief executive was paid a total of $3.4M for the year ended Dec 31, 2025. In the last 12 months, Whitehawk Therapeutics's executives and directors bought no stock on the open market and sold $2.6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.